New research presented at the Society of Nuclear medicine and Molecular Imaging (SNMMI) Annual Meeting shows that the targeted Radionuclide Alpha therapy, 225Ac-DOTATATE, has long-term anti-tumor effects against advanced gastroenteropancreatic #neuroendocrinetumors (GEP-NETs).

This study won the SNMMI Abstract of the Year Award.

225Ac-DOTATATE is a promising therapy option that adds a new dimension to the treatment of end-stage GEP-NETs, especially for patients who have tried all other standard therapy options,” Dr. Bal said. “These results warrant a phase 3, randomized, controlled trial to assess the true efficacy of 225Ac-DOTATATE versus 177Lu-DOTATATE.” Chandrasekhar S. Bal, Department of Nuclear medicine and PET at the All India Institute of Medical Science in New Delhi, India.

Read the article >>